RU2005131422A - Способы лечения болезни паркинсона - Google Patents
Способы лечения болезни паркинсона Download PDFInfo
- Publication number
- RU2005131422A RU2005131422A RU2005131422/15A RU2005131422A RU2005131422A RU 2005131422 A RU2005131422 A RU 2005131422A RU 2005131422/15 A RU2005131422/15 A RU 2005131422/15A RU 2005131422 A RU2005131422 A RU 2005131422A RU 2005131422 A RU2005131422 A RU 2005131422A
- Authority
- RU
- Russia
- Prior art keywords
- parkinson
- disease
- agent
- levodopa
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (23)
1. Применение первого средства, выбранного из сафинамида, производного сафинамида или ингибитора МАО-В, в комбинации со вторым средством, выбранным из, по меньшей мере, одного средства для лечения болезни Паркинсона, для изготовления лекарственного средства в виде комбинированного продукта для одновременного, раздельного или последовательного введения для лечения болезни Паркинсона.
2. Применение по п.1, где первое средство представляет собой сафинамид.
3. Применение по п.1, где первое средство представляет собой производное сафинамида.
4. Применение по п.3, где производное сафинамида выбрано из группы, состоящей из (S)-2-(4-бензилоксибензиламино)пропионамида; 2-[4-(3-хлорбензилокси)фенетил]аминоацетамида; 2-{[4-(3-хлорбензилокси)бензил]метиламиноацетамида; 2-(4-(3-хлорбензилокси)бензиламино)ацетамида; (S)-(+)-2-[4-(2-фторбензилокси)бензиламино]пропанамида; (S)-(+)-2-[4-(4-фторбензилокси)бензиламино]пропанамида; (S)-(+)-2-[4-(3-хлорбензилокси)бензиламино]пропанамида; (R)-(-)-2-[4-(3-хлорбензилокси)бензиламино]-3-гидроксипропанамида; (S)-(+)-2-{4-[2-(3-фторфенил)этил]оксибензил}-амино]пропанамида; 2-[4-(3-фторбензилокси)бензиламино]-2-метилпропанамида; и 2-[4-(3-бромбензилокси)бензиламино]-2-метилпропанамида.
5. Применение по п.1, в котором первое средство представляет собой ингибитор МАО-В.
6. Применение по п.5, в котором первое средство выбрано из группы, состоящей из селегилина, расагилина, лазабемида и кароксазона.
7. Применение по п.1, где указанное второе средство включает, по меньшей мере, один агонист допамина.
8. Применение по п.7, где указанный, по меньшей мере, один агонист допамина выбран из группы, состоящей из бромкриптина, каберголина, лисурида, перголида, ропинирола, апоморфина, суманирола, ротиготина, талипексола, дигидроэргокриптина и прамипексола.
9. Применение по п.1, где указанное второе средство включает леводопа/PDI.
10. Способ по п.9, где указанный леводопа/PDI выбран из группы, состоящей из леводопа плюс карбидопа (SINIMET®), леводопа плюс карбидопа контролируемого высвобождения (SINIMET-CR®), леводопа плюс бенсеразид (MADOPAR®), леводопа плюс бенсеразид контролируемого высвобождения (MADOPAR-HBS).
11. Применение по п.1, где указанное второе средство дополнительно включает ингибитор катехол-О-метилтрансферазы.
12. Применение по п.11, где указанный ингибитор катехол-О-метилтрансферазы представляет собой толкапон или энтакапон.
13. Применение по п.1, где указанное второе средство дополнительно включает амантидин.
14. Набор для лечения пациента, имеющего болезнь Паркинсона, включающий терапевтически эффективную дозу первой композиции, включающей сафинамид, производное сафинамида или ингибитор МАО-В, и второй композиции, включающей, по меньшей мере, одно средство для лечения болезни Паркинсона, для лечения или, по меньшей мере, частичного облегчения симптомов болезни Паркинсона, или в одной и той же, или в отдельной упаковке, и инструкции по его применению.
15. Набор по п.14, где указанная вторая композиция для лечения болезни Паркинсона включает, по меньшей мере, один из агониста допамина, леводопа/PDI, ингибитора катехол-О-метилтрансферазы и амантидина.
16. Фармацевтическая композиция, включающая эффективные количества сафинамида или его производного и одно или несколько средств для лечения болезни Паркинсона.
17. Фармацевтическая композиция, включающая эффективные количества ингибитора МАО-В и одно или несколько средств для лечения болезни Паркинсона.
18. Фармацевтическая композиция по любому из п.16 или 17, где указанное одно или несколько средств для лечения болезни Паркинсона включает, по меньшей мере, одно из агониста допамина, леводопа/PDI, ингибитора катехол-О-метилтрансферазы и амантидина.
19. Фармацевтическая композиция по любому из п.16 или 17, где одно или несколько средств для лечения болезни Паркинсона включает агонист допамина.
20. Фармацевтическая композиция по любому из п.16 или 17, где одно или несколько средств для лечения болезни Паркинсона включает леводопа/PDI в эффективном количестве для лечения болезни Паркинсона.
21. Фармацевтическая композиция по любому из п.16 или 17, где одно или несколько средств для лечения болезни Паркинсона включает леводопа/PDI и ингибитор катехол-О-метилтрансферазы.
22. Фармацевтическая композиция по любому из п.16 или 17, где одно или несколько средств для лечения болезни Паркинсона включает леводопа/PDI и ингибитор катехол-О-метилтрансферазы и агонист допамина.
23. Фармацевтическая композиция по любому из п.16 или 17, где одно или несколько средств для лечения болезни Паркинсона включает леводопа/PDI и ингибитор катехол-О-метилтрансферазы, агонист допамина и амантидин.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46220503P | 2003-04-11 | 2003-04-11 | |
| US60/462,205 | 2003-04-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005131422A true RU2005131422A (ru) | 2006-04-27 |
| RU2342929C2 RU2342929C2 (ru) | 2009-01-10 |
Family
ID=33159845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005131422/15A RU2342929C2 (ru) | 2003-04-11 | 2004-04-08 | Способы лечения болезни паркинсона |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8283380B2 (ru) |
| EP (2) | EP2070526B1 (ru) |
| JP (2) | JP2006522800A (ru) |
| KR (2) | KR20110070929A (ru) |
| CN (2) | CN102274517B (ru) |
| AR (1) | AR044007A1 (ru) |
| AT (1) | ATE435012T1 (ru) |
| AU (1) | AU2004228782B2 (ru) |
| BR (1) | BRPI0409364A (ru) |
| CA (1) | CA2523188C (ru) |
| CY (3) | CY1109295T1 (ru) |
| DE (1) | DE602004021790D1 (ru) |
| DK (2) | DK1613296T3 (ru) |
| ES (2) | ES2454272T3 (ru) |
| FR (1) | FR15C0054I2 (ru) |
| HU (1) | HUS1500043I1 (ru) |
| IL (2) | IL171331A (ru) |
| LU (1) | LU92782I2 (ru) |
| MX (1) | MXPA05010873A (ru) |
| NL (1) | NL300752I2 (ru) |
| NO (3) | NO334316B1 (ru) |
| NZ (1) | NZ542910A (ru) |
| PL (2) | PL1613296T3 (ru) |
| PT (2) | PT2070526E (ru) |
| RU (1) | RU2342929C2 (ru) |
| SI (2) | SI2070526T1 (ru) |
| TW (1) | TWI340640B (ru) |
| WO (1) | WO2004089353A2 (ru) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| ES2253579T3 (es) * | 2001-09-03 | 2006-06-01 | Newron Pharmaceuticals S.P.A. | Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico. |
| EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| EP1658062B1 (en) * | 2003-08-25 | 2010-02-17 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| RS51411B (en) * | 2004-09-10 | 2011-02-28 | Newron Pharmaceuticals S.P.A. | USE (R) - (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDE AS SELECTIVE MODULATORS OF SODIUM AND / OR CALCIUM CHANNELS |
| US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
| US8772346B2 (en) | 2005-11-09 | 2014-07-08 | Torrent Pharmaceuticals Limited | Pharmaceutical composition |
| BRPI0620239B8 (pt) * | 2005-12-22 | 2021-05-25 | Newron Pharm Spa | derivados de 2-feniletilamino. |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| US8106056B2 (en) * | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
| EP2474521B1 (en) * | 2006-06-19 | 2016-08-10 | Newron Pharmaceuticals S.p.A. | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them |
| DE102007014947B4 (de) * | 2007-03-23 | 2010-05-27 | Axxonis Pharma Ag | Stabilisierte wässrige Lösungen von Ergolinverbindungen |
| JP2010525018A (ja) * | 2007-04-24 | 2010-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物 |
| LT2155663T (lt) | 2007-06-15 | 2018-02-12 | Newron Pharmaceuticals S.P.A. | Pakeisti 2-[2-(fenil)etilamino]alkanamidų dariniai ir jų, kaip natrio ir (arba) kalcio kanalų moduliatorių, panaudojimas |
| GB2453770A (en) * | 2007-10-19 | 2009-04-22 | Reckitt Benckiser Healthcare | Oral composition comprising a cooling agent |
| WO2009054964A1 (en) * | 2007-10-22 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Alpha-aminoamide derivatives |
| CN104523668B (zh) | 2007-12-11 | 2020-06-09 | 纽朗制药有限公司 | 高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类及其用途 |
| EP2222290B1 (en) * | 2007-12-19 | 2021-06-16 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives for the treatment of psychiatric disorders |
| WO2009122351A2 (en) * | 2008-04-01 | 2009-10-08 | Kangwon National University | Anti-parkinsonian compounds mppe |
| WO2009147432A1 (en) * | 2008-06-02 | 2009-12-10 | Generics [Uk] Limited | An improved process for the preparation of amines |
| WO2009147430A1 (en) * | 2008-06-02 | 2009-12-10 | Generics [Uk] Limited | A process for the preparation of enantiomerically pure amines |
| US8969417B2 (en) * | 2008-06-06 | 2015-03-03 | Pharmatwob Ltd. | Pharmaceutical compositions for treatment of Parkinsons disease |
| US20090312436A1 (en) * | 2008-06-13 | 2009-12-17 | Ruth Levy | Rasagiline for parkinson's disease modification |
| WO2010010138A1 (en) * | 2008-07-24 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease |
| EP2218444A3 (en) * | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| US8080584B2 (en) | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| CN102048717B (zh) | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| WO2011098456A1 (en) * | 2010-02-09 | 2011-08-18 | Merck Serono S.A. | Safinamide in the treatment of dyskinesia |
| BR112012027623B1 (pt) | 2010-04-27 | 2021-07-06 | Newron Pharmaceuticals S.P.A. | Processo para a produção de sais de ralfinamida metanossulfonato ou seus renantiômeros, forma pseudopolimorfa de hemi-hidrato cristalino h do sal de metanossulfonato de ralfinamida, ou seu r-enantiômero, seu uso e formulação farmacêutica que o compreende |
| CN102985082A (zh) | 2010-04-30 | 2013-03-20 | 帝国制药美国公司 | 丙炔基氨基茚满透皮组合物 |
| CN103476404B (zh) | 2011-03-24 | 2017-09-29 | 帝国制药美国公司 | 包含活性剂层和活性剂转化层的透皮组合物 |
| WO2013028639A1 (en) | 2011-08-19 | 2013-02-28 | The Trustees Of Princeton University | C-halogen bond formation |
| US20150031768A1 (en) * | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
| WO2013070526A1 (en) | 2011-11-09 | 2013-05-16 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
| KR101856515B1 (ko) | 2012-11-02 | 2018-05-10 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 프로피닐아미노인단 경피 조성물 |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| US10111879B2 (en) | 2013-06-27 | 2018-10-30 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| AU2014391721B2 (en) * | 2014-04-21 | 2020-07-16 | Civitas Therapeutics, Inc. | Rapid relief of motor fluctuations in Parkinson's Disease |
| ES2774800T3 (es) | 2014-10-02 | 2020-07-22 | Megabiowood Co Ltd | Compuesto derivado de alfa-aminoamida y composición farmacéutica que contiene el mismo |
| LT3341380T (lt) * | 2015-08-27 | 2020-01-10 | Prexton Therapeutics Sa | Chromono oksimo darinys, prasiskverbiantis į smegenis, skirtas levadopa sukeltos diskinezijos gydymui |
| KR20230038214A (ko) * | 2016-03-17 | 2023-03-17 | 더 존스 홉킨스 유니버시티 | Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법 |
| ITUA20163981A1 (it) | 2016-05-31 | 2017-12-01 | Zambon Spa | Composizioni farmaceutiche comprendenti safinamide |
| EP3568082A4 (en) * | 2017-01-14 | 2020-12-09 | Neurrx, SPC | METHOD OF USING HUMAN EXCREMENTS AND SECRETS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE |
| CN109251155A (zh) * | 2017-07-14 | 2019-01-22 | 广东东阳光药业有限公司 | α-氨基酰胺衍生物及其用途 |
| EP3668501A4 (en) * | 2017-08-17 | 2021-03-17 | Zi-Qiang Gu | PAMOATE SALT OF MONOAMINE AGAINST PARKINSON, METHOD OF PREPARATION THEREOF AND USE |
| WO2019086408A1 (en) | 2017-11-02 | 2019-05-09 | Zambon S.P.A. | Pharmaceutical compositions comprising safinamide |
| KR102005019B1 (ko) * | 2018-04-04 | 2019-07-31 | 한국과학기술연구원 | 뇌졸중의 예방 및 치료용 조성물 |
| US11083715B2 (en) * | 2019-09-12 | 2021-08-10 | Achieve Life Sciences, Inc. | Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof |
| CN110938014A (zh) * | 2019-11-28 | 2020-03-31 | 岳千奥 | 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物 |
| CN112915083A (zh) * | 2019-12-06 | 2021-06-08 | 上海医药集团股份有限公司 | 药物组合物、成套药盒及其应用 |
| CN110999980A (zh) * | 2019-12-19 | 2020-04-14 | 新疆石河子职业技术学院（石河子市技工学校） | 一种葡萄酒洗浸奶酪加工方法 |
| US20230181508A1 (en) * | 2020-08-31 | 2023-06-15 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
| US3795739A (en) * | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
| US4049663A (en) | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| US4935429A (en) | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
| EP0252290B1 (en) * | 1986-06-10 | 1992-06-03 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof |
| JP2736103B2 (ja) | 1988-03-01 | 1998-04-02 | ヴァルター・ビルクマイヤー | パーキンソン症候群の治療用医薬、およびその製造方法 |
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5502658A (en) | 1990-12-27 | 1996-03-26 | Relin; Arkadi | Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity |
| GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| MX9709112A (es) * | 1995-05-26 | 1998-02-28 | Pfizer | Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato. |
| GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| FR2829027A1 (fr) * | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
-
2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/en not_active Expired - Lifetime
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
- 2004-04-08 CA CA2523188A patent/CA2523188C/en not_active Expired - Lifetime
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Application Discontinuation
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 EP EP04726590A patent/EP1613296B1/en not_active Expired - Lifetime
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko active Protection Beyond IP Right Term
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/en active Application Filing
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
-
2005
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
-
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
-
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
-
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
-
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
-
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Lifetime
-
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I1/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-22 LU LU92782C patent/LU92782I2/xx unknown
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005131422A (ru) | Способы лечения болезни паркинсона | |
| JP2006522800A5 (ru) | ||
| BRPI0413000A (pt) | uso de rotigotina para o tratamento de depressão | |
| EP2260850A3 (en) | A2A receptor antogonists for use in the treatment of movement disorders | |
| JP2012092127A5 (ru) | ||
| HRP20110230T1 (hr) | Derivati alfa-aminoamida korisni u tretmanu poremećaja uzrokovanih ovisnošću | |
| HRP20161039T1 (hr) | Deuterirani derivati kateholamina i lijekovi koji sadrže navedene spojeve | |
| EA201290865A1 (ru) | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона | |
| RU2008115239A (ru) | 7-[2-[4-(6-фтор-3-метил-1, 2-бензизоксазол-5-ил)-1-пиперазинил]этил]-2-(пропинил)-7h-пиразоло-[4,3-е]-[1,2,4]-триазоло-[1,5-с]пиримидин-5-амин | |
| MXPA06001815A (es) | Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson. | |
| RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
| RU2005137704A (ru) | 3-фторпиперидины в качестве антагонистов nmda/nr2b | |
| WO2006037061A3 (en) | Compositions and methods of using d-dopa to treat parkinson's disease | |
| Loewen et al. | Pharmacokinetics of opicapone and effect on COMT and levodopa pharmacokinetics in patients with Parkinson’s disease | |
| MX2010001702A (es) | Farmaco para aliviar las complicaciones motoras o los sintomas psiquiatricos de la enfermedad de parkinson. | |
| JP2003523993A5 (ru) | ||
| DE60125062D1 (de) | Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten | |
| JP2003523995A5 (ru) | ||
| UA94043C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения перивентрикулярной лейкомалации | |
| Jost et al. | Workshop III: Late motor complications of Parkinson's disease | |
| JP2023082771A (ja) | パーキンソン病治療薬 | |
| WO2024220909A1 (en) | Polymer film antiperspirant and grip enhancer | |
| JP2007511577A5 (ru) | ||
| McKeown et al. | Parkinsonism/Parkinson’s Disease | |
| Zauber et al. | Dyskinesias in Parkinsonian Syndromes |